aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
6.11
-0.10 (-1.69%)
At close: Nov 13, 2026, 4:00 PM EST
6.34
+0.24 (3.87%)
After-hours: Nov 13, 2026, 7:38 PM EST
aTyr Pharma Employees
As of December 31, 2025, aTyr Pharma had 60 total employees, including 58 full-time and 2 part-time employees. The number of employees increased by 1 or 1.69% compared to the previous year. That makes aTyr Pharma the 34,182nd largest employer in the world and 4,523rd in the United States.
Employees
60
Change (1Y)
1
Growth (1Y)
1.69%
Revenue / Employee
n/a
Profits / Employee
-$888,733
Market Cap
15.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 60 | 1 | 1.69% | 58 | 2 |
| Dec 31, 2024 | 59 | 0 | - | 56 | 3 |
| Dec 31, 2023 | 59 | -11 | -15.71% | 56 | 3 |
| Dec 31, 2022 | 70 | 17 | 32.08% | 65 | 5 |
| Dec 31, 2021 | 53 | 10 | 23.26% | 49 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Acumen Pharmaceuticals | 61 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
| CervoMed | 15 |
| BioVie | 13 |
| Tvardi Therapeutics | 12 |
| Cocrystal Pharma | 10 |
ATYR News
- 2 days ago - aTyr Pharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - aTyr Pharma downgraded to Hold from Buy at Freedom Broker - TheFly
- 7 days ago - aTyr Pharma price target lowered to split-adjusted $6 at RBC Capital - TheFly
- 7 days ago - aTyr Pharma price target lowered to $35 from $280 at Piper Sandler - TheFly
- 8 days ago - aTyr Pharma reports Q3 EPS ($7.43), consensus ($4.00) - TheFly
- 8 days ago - aTyr Pharma Earnings release: Q3 2026 - Filings
- 8 days ago - aTyr Pharma Quarterly report: Q3 2026 - Filings
- 15 days ago - aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine - GlobeNewsWire